Q2 2024 Presentation and Q&A
How does this Q&A work:
This company invites all interested, both current investors and potential investors to participate in this event, ask questions directly on this page before the event starts and upvote those questions you would like addressed.
The company will address as many questions as possible, and focus on those questions most wanted by investors.
Speakers at this event:
5 Questions
Aug. 15, 2024
It seems like you have a lot of evidence of the positive outcomes of using SuPAR as an indicator. So the returning question, why is it so difficult to sell into hospitals and clinics and what have you learned from this process to make sure that next year the same time ViroGates is a bigger and better company with a more efficient sales approach?
Aug. 15, 2024
With your current guidance it could mean a flat H2 compared to H1 but also a better H2. Can you say anything in regards to what you see in H2 and if you expect it to better than H1?
Aug. 15, 2024
You have 8,7 DKKm in cash how long do you expect this to last and what are you doing to lower the loss for the rest of the year?
Aug. 15, 2024
The new guidance is a significant down take, and EBIT is actually lower then 2023. What specific changes are you making for the rest of 2024 and to get a strong 2025?
Aug. 15, 2024
You mentioned in your latest guidance update that you are focusing all effort on short term revenue value, is there a risk here that you end up sacrificing the best long term possibilities by looking and focusing short term?